Personalization of Care for Castration-Resistant Prostate Cancer and the Evolving Role of Immunotherapy

Although most prostate tumors initially respond to androgen-deprivation therapies, tumors eventually develop the ability to grow and ultimately metastasize in the absence of androgens. There remains an important clinical need for improved strategies in the setting of castration-resistant prostate cancer. Advances in immunological sciences have allowed for the development of immune-targeted approaches specifically designed to treat these tumors. A number of these strategies are either available or in late-stage development.

This webcast which is based on the content of a case-based satellite symposium that took place at AUA will assess current and emerging immune-based methods to manage castration-resistant prostate cancer. During this program, immunological mechanisms that have been investigated for their utility in the setting of prostate cancer will be explored. Clinical trial results will be discussed and assessed in the context of their impact on state-of-the-art care to manage these difficult-to-treat forms of prostate cancer.

Additionally, an interactive panel discussion will explore important topics that require clinical consideration to individualize treatment and optimize management of castration-resistant disease.

Available until August 10, 2012.
Physicians: 1.25 AMA PRA Category 1 Credits^™
Nurses: 1.25 contact hours

This activity is jointly sponsored by SCEPTER™ and Quintiles Medical Education. This activity is co-provided by Global Education Group and SCEPTER™.